Avita Medical (ASX: AVH) received US Food and Drug Administration approval for its premarket approval supplement for the Recell Go mini, a disposable cartridge designed to treat smaller wounds up to 480 square centimeters, according to a Tuesday filing with the Australian bourse.
This extends the company's Recell Go platform, which previously handled larger wounds up to 1,920 square centimeters, the filing said.
The regenerative medicine company plans to roll out the product in the first quarter of 2025, targeting broader access to smaller wound care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.